REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant
(NASDAQ: CLGN), a regenerative and aesthetics medicine
company, today announced the appointment of Hugh Evans to its Board of Directors, increasing
the board to six independent members.
U.S.-based Mr. Evans brings extensive board, 3D printing
technology, and investment experience to CollPlant. He currently
serves on the boards of four manufacturing technology companies
including Factory Four, ZVerse, 3DM, and is also a Non-Executive
Chairman of Culinary Printworks. He was formerly a board member of
AquaVenture Holdings, which was acquired by Culligan
International.
Mr. Evans served as Senior Vice President of Corporate
Development & Digitization at 3D Systems Corporation, a leading
3D printing company, where he led M&A, venture capital
investments, joint ventures, and technology licensing. Previously,
he served as a portfolio manager at T. Rowe Price Associates in
Baltimore, Maryland for over 20
years.
"Hugh brings significant insights and experience that will be
invaluable to CollPlant as we continue to execute our strategic
vision. His achievements as a senior executive and board member,
complemented by his notable expertise in the 3D printing industry
will undoubtedly serve us well as we continue to grow, " said
Yehiel Tal, CollPlant Chief
Executive Officer. "Hugh is an excellent addition to our board of
directors and will play an integral role in our mission to help
people live longer and better through our innovative collagen
technology."
"I'm thrilled to join CollPlant's board at a pivotal time in the
Company's mission to revolutionize the fields of regenerative
and aesthetic medicine via its rhCollagen technology platform,"
said Mr. Evans. "I look forward to contributing from my experience
in additive manufacturing to support CollPlant in pioneering novel
solutions for patients around the world."
CollPlant's Chairman, Dr. Roger J.
Pomerantz commented, "Hugh has a deep understanding and
appreciation of CollPlant's technology and how it can be
transformative in advancing the 3D bioprinting field. We are very
pleased to welcome him to the board and look forward to his
guidance and support."
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. The Company's products are based on its rhCollagen
(recombinant human collagen) produced with CollPlant's proprietary
plant based genetic engineering technology. These products address
indications for the diverse fields of tissue repair, aesthetics,
and organ manufacturing, and are ushering in a new era in
regenerative and aesthetic medicine. CollPlant recently
entered a development and global commercialization agreement for
dermal and soft tissue fillers with Allergan, an AbbVie company,
the global leader in the dermal filler market.
For more information, visit http://www.collplant.com.
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the impact of the COVID-19
pandemic; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk and products for
medical aesthetics; the Company's ability to obtain favorable
pre-clinical and clinical trial results; regulatory action with
respect to rhCollagen based BioInk and medical aesthetics products
including but not limited to acceptance of an application for
marketing authorization review and approval of such application,
and, if approved, the scope of the approved indication and
labeling; commercial success and market acceptance of the Company's
rhCollagen based products in 3D Bioprinting and medical aesthetics;
the Company's ability to establish sales and marketing capabilities
or enter into agreements with third parties and its reliance on
third party distributors and resellers; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the Company's reliance on third parties to conduct
some or all aspects of its product manufacturing; the scope of
protection the Company is able to establish and maintain for
intellectual property rights and the Company's ability to operate
its business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the Company operates;
projected capital expenditures and liquidity; changes in the
Company's strategy; and litigation and regulatory proceedings. More
detailed information about the risks and uncertainties affecting
CollPlant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the
SEC, and in other filings that CollPlant has made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's current views with respect to future
events, and CollPlant does not undertake and specifically disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran
Rotem
Deputy CEO & Chief Financial Officer
Tel: + 972-73-2325600/631
Email: Eran@collplant.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/collplant-appoints-additive-manufacturing-executive-hugh-evans-to-its-board-of-directors-301257385.html
SOURCE CollPlant